Ann Hynes
Stock Analyst at Mizuho
(4.35)
# 361
Out of 5,128 analysts
279
Total ratings
62.98%
Success rate
12.03%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGRY Surgery Partners | Maintains: Outperform | $22 → $19 | $15.64 | +21.48% | 4 | Dec 18, 2025 | |
| HCA HCA Healthcare | Maintains: Outperform | $505 → $520 | $470.65 | +10.49% | 23 | Dec 18, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $11 → $13 | $17.49 | -25.67% | 6 | Dec 18, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $174 → $200 | $216.77 | -7.74% | 4 | Dec 18, 2025 | |
| BTSG BrightSpring Health Services | Maintains: Outperform | $38 → $42 | $39.51 | +6.30% | 3 | Dec 18, 2025 | |
| ARDT Ardent Health | Maintains: Outperform | $20 → $12 | $9.03 | +32.89% | 4 | Dec 18, 2025 | |
| ACHC Acadia Healthcare Company | Maintains: Neutral | $22 → $17 | $13.71 | +24.00% | 13 | Dec 18, 2025 | |
| CVS CVS Health | Maintains: Outperform | $88 → $95 | $79.79 | +19.06% | 12 | Dec 10, 2025 | |
| ELV Elevance Health | Maintains: Outperform | $420 → $400 | $366.69 | +9.08% | 6 | Nov 4, 2025 | |
| MEDP Medpace Holdings | Maintains: Outperform | $575 → $655 | $613.09 | +6.84% | 5 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $194 → $225 | $202.00 | +11.39% | 16 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $210 | $178.14 | +17.88% | 16 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $320 | $253.73 | +26.12% | 16 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $430 | $341.70 | +25.84% | 21 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $345 | $275.06 | +25.43% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $28 → $40 | $45.77 | -12.61% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $225 | $244.29 | -7.90% | 13 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $173 → $225 | $202.92 | +10.88% | 16 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $330 | $176.38 | +87.10% | 9 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $21.93 | -31.60% | 11 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $110 → $120 | $207.19 | -42.08% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $19.50 | +43.59% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $106.37 | -10.69% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $279.12 | +37.93% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $208.39 | -4.03% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $2.13 | +12,482.16% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $823.95 | -38.71% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $0.94 | +5,963.83% | 1 | Sep 21, 2017 |
Surgery Partners
Dec 18, 2025
Maintains: Outperform
Price Target: $22 → $19
Current: $15.64
Upside: +21.48%
HCA Healthcare
Dec 18, 2025
Maintains: Outperform
Price Target: $505 → $520
Current: $470.65
Upside: +10.49%
Fortrea Holdings
Dec 18, 2025
Maintains: Neutral
Price Target: $11 → $13
Current: $17.49
Upside: -25.67%
Charles River Laboratories International
Dec 18, 2025
Maintains: Neutral
Price Target: $174 → $200
Current: $216.77
Upside: -7.74%
BrightSpring Health Services
Dec 18, 2025
Maintains: Outperform
Price Target: $38 → $42
Current: $39.51
Upside: +6.30%
Ardent Health
Dec 18, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $9.03
Upside: +32.89%
Acadia Healthcare Company
Dec 18, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $13.71
Upside: +24.00%
CVS Health
Dec 10, 2025
Maintains: Outperform
Price Target: $88 → $95
Current: $79.79
Upside: +19.06%
Elevance Health
Nov 4, 2025
Maintains: Outperform
Price Target: $420 → $400
Current: $366.69
Upside: +9.08%
Medpace Holdings
Oct 24, 2025
Maintains: Outperform
Price Target: $575 → $655
Current: $613.09
Upside: +6.84%
Oct 17, 2025
Maintains: Outperform
Price Target: $194 → $225
Current: $202.00
Upside: +11.39%
Oct 17, 2025
Maintains: Outperform
Price Target: $190 → $210
Current: $178.14
Upside: +17.88%
Oct 17, 2025
Maintains: Outperform
Price Target: $285 → $320
Current: $253.73
Upside: +26.12%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $430
Current: $341.70
Upside: +25.84%
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $345
Current: $275.06
Upside: +25.43%
Oct 9, 2025
Maintains: Neutral
Price Target: $28 → $40
Current: $45.77
Upside: -12.61%
Jul 25, 2025
Maintains: Outperform
Price Target: $190 → $225
Current: $244.29
Upside: -7.90%
Jul 25, 2025
Maintains: Outperform
Price Target: $173 → $225
Current: $202.92
Upside: +10.88%
Jul 11, 2025
Maintains: Outperform
Price Target: $400 → $330
Current: $176.38
Upside: +87.10%
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $21.93
Upside: -31.60%
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $207.19
Upside: -42.08%
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $19.50
Upside: +43.59%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $106.37
Upside: -10.69%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $279.12
Upside: +37.93%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $208.39
Upside: -4.03%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $2.13
Upside: +12,482.16%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $823.95
Upside: -38.71%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $0.94
Upside: +5,963.83%